echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shuanglu Pharmaceutical's long-acting recombinant human glucagon-like peptide-1 injection was approved for clinical use

    Shuanglu Pharmaceutical's long-acting recombinant human glucagon-like peptide-1 injection was approved for clinical use

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 5, Shuanglu Pharmaceutical issued an announcement stating that it had recently received the "Drug Clinical Trial Approval Notice" (notice number : 2021LP01795, 2021LP01796), agreed to carry out clinical trials for type 2 diabetes indications


    Long-acting recombinant human glucagon-like peptide-1 injection is a glucagon-like peptide (GLP-1) receptor agonist, which can effectively treat type 2 diabetes


    In February 2019, Eli Lilly’s weekly preparation of GLP-1 receptor agonist dulaglutide (Duyida®) was approved to enter the domestic market


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.